Skip to main content
. 2015 Aug 28;21(32):9512–9525. doi: 10.3748/wjg.v21.i32.9512

Figure 5.

Figure 5

Results of a randomized controlled trial of Sunitinib vs placebo for well-differentiated pancreatic neuroendocrine tumors demonstrating (A) progression free survival and (B) overall survival. From: Raymond et al[98]. Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors. N Engl J Med 2011; 364: 501-513.